Epha2 agonistic monoclonal antibodies and methods of use thereof
CA 2485548 A1 · Owner: Purdue Research Foundation · Inventors: Stewart, Jane C.; Carles-Kinch, Kelly; Kinch, Michael S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer particularly, metastatic , cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2 thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not noncancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 12, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 12, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 12, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.